A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS
EHA Learning Center, Claire Burney, 181515
GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS
EHA Learning Center, Guillermo Guenechea, 181516
STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY
EHA Learning Center, Adeline Wannez, 181517
DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?
EHA Learning Center, SUJATA BHOI, 181531
ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY
EHA Learning Center, Andrew Rawstron, 181532
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS
EHA Learning Center, Basile Stamatopoulos, 181533
A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL
EHA Learning Center, Franke Georg-Nikolaus, 181548
VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS
EHA Learning Center, Inge G.P. Geelen, 181549
FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP
EHA Learning Center, Hirohisa Nakamae, 181550
IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION
EHA Learning Center, Novella Pugliese, 181564
LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN'S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM
EHA Learning Center, Katherine Byrne, 181565
CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.
EHA Learning Center, Hayder Saeed, 181566
DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY
EHA Learning Center, Graca Porto, 181580
FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE COMPLEX IN WOMEN WITH IRON DEFICIENCY ANEMIA - A RANDOMISED CONTROLLED TRIAL
EHA Learning Center, Garima Chaudhry, 181581
GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY
EHA Learning Center, Amit Sud, 181582
GENETIC CONFIRMATION AND FINDING NOVEL MUTATIONS IN GLANZMANN THROMBASTHENIA AND VON WILLEBRAND DISEASE FAMILIES BY DIAGNOSTIC EXOME SEQUENCING
EHA Learning Center, Ye Jee Shim, 181597
HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Irina Zotova, 181598
AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA
EHA Learning Center, Aukje Kreuger, 181599
PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.
EHA Learning Center, Mattia D'Agostino, 181609
TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA
EHA Learning Center, Salomon Manier, 181610
DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMIDS
EHA Learning Center, Konstantinos Dimopoulos, 181611
AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Learning Center, Meletios A Dimopoulos, 181625
THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)
EHA Learning Center, Jesus F. San Miguel, 181626
FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB (MPV) IN PATIENTS ≥ 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY
EHA Learning Center, Sonja Zweegman, 181627
LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER?
EHA Learning Center, Venton Geoffroy, 181641
INCIDENCE AND OUTCOME OF SECONDARY NON HEMATOLOGICAL CANCERS IN ADULT PATIENTS WITH MASTOCYTOSIS
EHA Learning Center, M Bonifacio, 181642
HIGH WBC COUNT WAS THE RISK FACTOR FOR SURVIVAL IN PATIENTS WITH CSF3R- MUTATED CHRONIC NEUTROPHILIC LEUKEMIA
EHA Learning Center, Qian Jiang, 181643
IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME.
EHA Learning Center, Silvy Lachance, 181658
ACUTE MYELOID LEUKEMIA (AML) TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALLY-INSURED POPULATION
EHA Learning Center, Karen Chung, 181659
HEALTH-RELATED QUALITY OF LIFE IN AL AMYLOIDOSIS PATIENTS WITH NERVOUS SYSTEM INVOLVEMENT
EHA Learning Center, tiffany quock, 181660
COMPARABLE LONG-TERM OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR OLDER PATIENTS (AGE ≥50 YEARS) WITH AML FROM SIBLING AND MATCHED UNRELATED DONORS. A REPORT ON BEHALF OF THE ALWP OF EBMT.
EHA Learning Center, A Shimoni, 181675
IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Jun Aoki, 181676
LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT
EHA Learning Center, Yue Han, 181677
A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MIRASOL PATHOGEN REDUCTION TECHNOLOGY
EHA Learning Center, Laura Gutierrez, 181691
USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING
EHA Learning Center, Dana Warcel, 181692
SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING
EHA Learning Center, Matthew Healey, 181693
IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL.
EHA Learning Center, Rachel Mitchell, 181447
PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY
EHA Learning Center, Grigory Tsaur, 181448
THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA
EHA Learning Center, Edwige VOISSET, 181463
DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENISIS
EHA Learning Center, Jan-Henning Klusman, 181464
IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS
EHA Learning Center, Uma Borate, 181481
MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA
EHA Learning Center, Tomohiro Yabushita, 181483
OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA
EHA Learning Center, Bruno Medeiros, 181497
NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION
EHA Learning Center, Tapan Kadia, 181498
HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Sheng-Yu Hung, 181499
NOVEL SMALL MOLECULE INHIBITORS CO-TARGETING CK1A AND P-TEF-B DISRUPT SUPER-ENHANCERS AND ERADICATE ACUTE MYELOID LEUKEMIA IN A MOUSE MODEL
EHA Learning Center, Yinon Ben-Neriah, 183935
TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP
EHA Learning Center, Peter Borchmann, 181437
REVERSIBLE PHARMACOLOGICAL TARGETING OF RHOA ALLOWS IMPROVED STORAGE, SURVIVAL AND HEMOSTATIC ACTIVITY OF PLATELETS IN VITRO AND IN VIVO, IN MICE AND IN PRIMATES.
EHA Learning Center, Shailaja Hegde, 181436
EXPOSURE TO INFECTION TRIGGERS PAX5 AND ETV6-RUNX1 CHILDHOOD BCP-ALL
EHA Learning Center, Julia Hauer, 181435
RE-CREATING HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN (HPFH) WITH CRISPR/CAS9 TO TREAT SICKLE CELL DISEASE (SCD) AND BETA-THALASSEMIA (BETA-THAL)
EHA Learning Center, Bill Lundberg, 181434
BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS
EHA Learning Center, Mattia Algeri, 181433
Myeloid malignancies
EHA Learning Center, Mario Cazzola, 184436
Novel Treatment Strategies In Waldenström's Macroglobulinemia
EHA Learning Center, Efstathios Kastritis, 184439
Risk Adapted Treatment Of CMML
EHA Learning Center, Eric Padron, 184445
Targeted next generation sequencing to improve diagnosis of rare anaemia
EHA Learning Center, Barnaby Clark, 184448
New approaches to MM
EHA Learning Center, Jesus F. San Miguel, 192907
What's new in the 2016 WHO lymphoma classification?
EHA Learning Center, Steven Swerdlow, 184435
Molecular Biology Of Waldenström's Disease
EHA Learning Center, Steven Treon, 184438
Clinical Heterogeneity Of Ambiguous Lineage Leukemias: Search For Optimal Treatment Strategy
EHA Learning Center, O. Hrusak, 184441
From Genetics To Epigenetics In Chronic Myelomonocytic Leukemia
EHA Learning Center, Eric Solary, 184444
Genetic Studies Of Human Erythropoiesis
EHA Learning Center, Vijay Sankaran, 184447
Molecular pathogenesis of Richter syndrome
EHA Learning Center, Gianluca Gaidano, 192912
José Carreras Lecture: AML: The Evil side of gene regulation
EHA Learning Center, Ruud Delwel, 184433
Introduction José Carreras Award & Lecture
EHA Learning Center, Shai Izraeli, 184432
Presentation EHA - José Carreras young investigator award & EHA research grants
EHA Learning Center, Martina Muckenthaler, 184431
Opening address
EHA Learning Center, Tony Green, 184430
PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF PREVIOUS PLASMA CELL-DIRECTED THERAPIES
EHA Learning Center, Morie Gertz, 181391
TP53 MUTATIONS, BUT NOT DELETION OF TP53 AND CDKN2A, HAVE INDEPENDENT PROGNOSTIC VALUE IN MANTLE CELL LYMPHOMA TREATED BY THE NORDIC (MCL2 AND MCL3) REGIMEN
EHA Learning Center, Christian Winther Eskelund, 181396
DEFINITION OF PARTIAL RESPONSE IN YOUNGER AML PATIENTS AFTER FIRST INDUCTION COURSE MAY BE EXTENDED BY INCLUSION OF IMMUNOPHENOTYPIC DETECTION OF MEASURABLE RESIDUAL DISEASE IN CR
EHA Learning Center, Sylvia Freeman, 181401
THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR (BCR) CROSS-TALK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
EHA Learning Center, Alexey Danilov, 181405
TRANSCRIPTOME SEQUENCING REVEALS DISTINCT SUBTYPES OF MYELODYSPLASIA WITH PROGNOSTIC SIGNIFICANCE
EHA Learning Center, Seishi Ogawa, 181410
DELETION OF THE F-BOX PROTEIN NIPA (NUCLEAR INTERACTION PARTNER OF ALK) IMPAIRS NPM-ALK DRIVEN TRANSFORMATION
EHA Learning Center, Lena Johanna Lippert, 181414
CD34+ AND HUMAN INDUCED PLURIPOTENT STEM CELL (IPSC) DIFFERENTIATION TO TRANSFUSION READY RED BLOOD CELLS
EHA Learning Center, Marie-Jose Claessen, 181419
METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA (AML)
EHA Learning Center, Paolo Gallipoli, 181423
A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS
EHA Learning Center, Dimitrios Karamitros, 181427
TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS CONFERS POTENT REACTIVITY AGAINST ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, HARDIKKUMAR JETANI, 181432
PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Wanggang Zhang, 181390
ANALYSIS AND CHARACTERIZATION OF HEMATOLOGIC CANCERS USING A COMPREHENSIVE NGS PANEL COMPRISED OF DNA AND RNA BAITS TARGETING 704 GENES
EHA Learning Center, Timothy Stenzel, 181395
LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY
EHA Learning Center, W Zeijlemaker, 181400
INTEGRATIVE ANALYSIS OF THE GENOME, EPIGENOME, TRANSCRIPTOME AND THREE-DIMENSIONAL CHROMATIN STRUCTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Renee Beekman, 181404
IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS
EHA Learning Center, Andrea Pellagatti, 181409
ALPHA-KETOGLUTURATE EXPOSES METABOLIC VULNERABILITIES IN B-CELL LYMPHOMAS
EHA Learning Center, Ricardo Aguiar, 181413
LONG-TERM HEALTH STATUS AFTER HSC TRANSPLANTATION FOR THALASSEMIA: THE FRENCH EXPERIENCE
EHA Learning Center, Isabelle THURET, 181418
INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Ileana Antony-Debre, 181422
SHORT-TERM FEEDING OF A HIGH-FAT DIET DISTURBS LIPID RAFT/TGF-ΒETA SIGNALING-MEDIATED QUIESCENCE OF HEMATOPOIETIC STEM CELLS IN C57BL/6J MOUSE BONE MARROW
EHA Learning Center, François Hermetet, 181426
FIRST EVIDENCE DEMONSTRATING ENGRAFTMENT AND REPOPULATION ADVANTAGE OF GENE-CORRECTED HEMATOPOIETIC REPOPULATING CELLS IN NON-CONDITIONED FANCONI ANEMIA PATIENTS
EHA Learning Center, Julian Sevilla, 181431
MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL
EHA Learning Center, Stefania Oliva, 181389
RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND SAFETY IN THE RANDOMIZED MABEASE STUDY IN FIRST-LINE DLBCL
EHA Learning Center, Pieternella Lugtenburg, 181394
GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION.
EHA Learning Center, Jurjen Versluis, 181399
THE VALUE OF NGS PANEL SEQUENCING TO MOLECULARLY DEFINE MYELOID MALIGNANCIES AND CLARIFY BORDERLINE CASES: A STUDY ON 39 GENES IN 1143 PATIENTS
EHA Learning Center, Constance Baer, 181408
DENOSUMAB INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA MAJOR AND OSTEOPOROSIS: RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, PHASE 2B CLINICAL TRIAL
EHA Learning Center, Ersi Voskaridou, 181417
BASELINE AND EARLY POST-TREATMENT CLINICAL AND LABORATORY FACTORS ASSOCIATED WITH SEVERE NEUROTOXICITY FOLLOWING 19-28Z CAR T CELLS IN ADULT PATIENTS WITH RELAPSED B-ALL
EHA Learning Center, Eric Smith, 181430
NEXT GENERATION SEQUENCING (NGS) METHODOLOGY FOR DETERMINING CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Christopher Chiu, 181387
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jesus San-Miguel, 181388
Car-T cells in AML
EHA Learning Center, A. Bondanza, 192911
CLINICAL IMPACT OF THE SUBCLONAL ARCHITECTURE AND MUTATIONAL COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Ferran Nadeu, 181402
FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ΑLPHA AND C-MYC IN CLL CELLS
EHA Learning Center, Viola Meyer-Pannwitt, 181403
LOW MYBL2 EXPRESSION OBSERVED IN MYELODYSPLASTIC SYNDROME PATIENTS WITH WORSE PROGNOSIS IS ASSOCIATED WITH ALTERED DNA REPAIR MECHANISMS IN HAEMATOPOETIC STEM CELLS
EHA Learning Center, Paloma García, 181406
FUNCTIONAL PROTEOMICS IDENTIFIES SETD2 AS A CRITICAL EFFECTOR OF MLL FUSION PROTEINS TO SAFEGUARD GENOMIC INTEGRITY.
EHA Learning Center, Anna Skucha, 181420
CEBPA-MUTANT ACUTE MYELOID LEUKEMIA IS SENSITIVE TO SMALL-MOLECULE-MEDIATED INHIBITION OF THE MENIN-MLL INTERACTION
EHA Learning Center, Luisa Schmidt, 181421